Skip to main content
OpenTrials
Completed

NCT Number: NCT00668122

Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections

To assess and compare the efficacy and safety of ciprofloxacin extended-release (CIPRO XR) tablet 1000 mg PO once-daily (OD) versus ciprofloxacin immediate-release (CIPRO IR) tablet 500 mg PO twice-daily (BID) for 7-14 days in patients with complicated and/or nosocomial urinary tract infections (cUTI).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Monza, Milano, Italy

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The primary diagnosis in this clinical trial was cUTI in men or non-pregnant women over 18 years of age. Other main inclusion criteria:

  • One or more clinical symptoms and signs of a lower UTI: fever (> 38°C, orally), chills, frequency of micturition, dysuria, urge sensation.
  • One or more of the following underlying conditions suggestive of cUTI:
  • Indwelling urinary catheter.
  • 100 mL of residual urine after voiding.
  • Neurogenic bladder.
  • Obstructive uropathy due to lithiasis, tumor or fibrosis.
  • Acute urinary retention in men.

Exclusion criteria

Diagnosis of pyelonephritis supported by clinical signs/symptoms of fever (>38°C orally), chills and flank pain (all 3 signs/symptoms must be present).

  • Have a history of allergy to quinolones
  • Are unable to take oral medication
  • Have an intractable infection requiring > 14 days of therapy
  • Have a requirement for concomitant administration of sucralfate or divalent and trivalent cations such as iron or antacids containing magnesium, aluminum or calcium
  • Have prostatitis or epididymitis
  • Have had a renal transplant
  • Have ileal loop or vesica- urethral reflux
  • Have significant liver or kidney impairment
  • Have a history of tendinopathy associated with fluoroquinolones
  • Are pregnant, nursing
  • Have a history of convulsions or CNS disorders

Treatment and study plan

Cipro XR (Ciprofloxacin, BAYQ3939)

Drug

Ciprofloxacin XR 1000 mg orally once a day

Cipro IR (Ciprofloxacin, BAYQ3939)

Drug

Ciprofloxacin IR 500 mg orally twice a day

Primary outcomes

  1. Bacteriological response 5 to 9 days after the last dose of study medication (TOC visit).

    Time frame: 5-9 days

Secondary outcomes

  1. Bacteriological outcome during treatment

    Time frame: 7-14 days

  2. Bacteriological outcome at follow-up

    Time frame: 28-42 days

  3. Clinical outcome during treatment

    Time frame: 7-14 days

  4. Clinical outcome at the test-of-cure visit

    Time frame: 5-9 days

  5. Clinical outcome at follow-up

    Time frame: 28-42 days

  6. Adverse event collection

    Time frame: 28-42 days

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Efficacy and Safety of Ciprofloxacin Extended-Release 1000 mg Once-Daily Versus Ciprofloxacin Immediate-Release 500 mg Twice-Daily Given 7-14 Days in Patients With Complicated Urinary Tract Infections: Prospective, Randomized, Double-Blind Trial.

Acronym: EMERON

Important dates

Study start
2004
Study completion
2006
First posted
Apr 28, 2008
Registry last updated
Jun 30, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.